-
Part 3 | Session 3 ACC 22: Results From the PACIFIC AF Trial
-
Part 3 | Session 5 ACC 22: Results from the TRANSLATE-TIMI 70 Trial
-
Part 3 | Session 6 ACC 22: Results from the POISE-3 Trial
-
Part 3 | Session 7 ACC 22: ICD Shock Therapies and the Burden of Ventricular Tachycardia
-
Part 3 | Session 9 ACC 22: Magnitude & Duration of Effects of a siRNA Targeting Lp(a)
-
Part 3 | Session 10 ACC 22: Results From a sub-study of the POISE-3 Trial
-
Part 3 | Session 11 ACC 22: Findings from the CoreValve US Pivotal & SURTAVI Trials
-
Part 3 | Session 12 ACC 22: ADAPT-TAVR Shows SLT Does Not Affect CO for Patients After TAVR
-
Part 3 | Session 13 ACC 22: Results From the Chocolate-Touch Study
-
Part 3 | Session 14 ACC 22: Results from the GIPS-IV Trial
-
Part 3 | Session 18 ACC 22: 3-year Efficacy Outcomes from the SPYRAL HTN-ON MED Med Pilot Study
-
Part 3 | Session 19 2022 AHA/ACC/HFSA Guideline for HF Management: Highlights & Implementation
-
Part 4 | Session 1 ACC 22: 3 Trials That Will Change Your Practice with Dr Purvi Parwani
-
Part 4 | Session 3 4 Lipid Late-breaker Highlights from ACC.22 with Dr Erin Michos
-
Part 1 | Session 1 ACC 22 Late-breaking Science Preview
-
Part 1 | Session 2 ACC.22 Late-breaking Science Wrap-Up
-
Part 2 | Session 1 ACC 2022 Late-breaker Discussion: The SODIUM-HF Trial
-
Part 2 | Session 2 ACC 2022 Late-breaker Discussion: The SuperWIN Trial
-
Part 2 | Session 3 ACC 22 Late-breaker Discussion: The PROMPT-HF Trial
-
Part 2 | Session 4 ACC 22 Late-breaker Discussion: The DIAMOND Trial
Our regular review series View from the Thoraxcenter hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provide a concise analysis of the late-breaking science results and spotlight impactful data.
For a deeper dive into key clinical trial data, Dr Harriette Van Spall (McMaster University, Hamilton, CA)talks with principal investigators in her regular Late-Breaker Discussion Series.
Short, accessible Expert Interviews were conducted with select faculty focusing on the results, applicability, and impact on future research.
More from this programme
Faculty Biographies

Milind Y Desai
Professor of Medicine
Dr Milind Desai works as the Director of the Hypertrophic Cardiomyopathy Center at the Heart, Vascular and Thoracic Institute at Cleveland Clinic. He also serves as a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine.
Alongside holding the Haslam Family Endowed Chair in Cardiovascular Medicine, Dr Desai has dual appointments in the Departments of Cardiovascular Medicine, within the Section of Cardiovascular Imaging, and Radiology. He is also a visiting professor at the University of Oxford, UK.
Dr Desai's clinical interests are heart valve disease, hypertrophic cardiomyopathy, aortic disorders, complex coronary artery disease, pericardial disease, and radiation heart disease. Dr Desai has a special interest in multimodality cardiovascular imaging, including echocardiogram, computed tomography (CT) scan and magnetic resonance imaging (MRI).